Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00108160 · ClinicalTrials.gov registry record · Phase 4

Preventing Staphylococcal (Staph) Infection

A Phase 4 study, sponsored by US Department of Veterans Affairs.

Completed
Registry status
Phase 4
Development phase
146
Enrollment target

NCT00108160 is a Phase 4 study that has completed, run by US Department of Veterans Affairs. The registered enrollment target is 146 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00108160, a Phase 4 study, has completed, sponsored by US Department of Veterans Affairs.

COMPLETED
Registry status
Phase 4
Development phase
146 participants
Enrollment target

Study Summary

The purpose of this study is to determine if mupirocin 2% in polyethylene glycol (PEG) ointment \[Treatment Arm\] is effective in preventing moderate to severe re-infection with Staphylococcus aureus compared with treatment with polyethylene glycol (PEG) ointment \[Placebo Arm\].

Interventions

  • DRUG Mupirocin Ointment [Treatment]
  • DRUG Polyethylene Glycol Ointment [Placebo]

Trial Details

FieldValue
Enrollment Target 146 participants
Start Date 2005-04
Est. Completion 2012-08
Phase Phase 4

Sponsor

US Department of Veterans Affairs

632 total trials

What the Registry Record Tells You About NCT00108160

The ClinicalTrials.gov registry entry for NCT00108160 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 146 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is US Department of Veterans Affairs, which has 632 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Mupirocin Ointment [Treatment] is the first listed.

NCT00108160 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00108160 about?

NCT00108160 is a clinical study titled "Preventing Staphylococcal (Staph) Infection". The purpose of this study is to determine if mupirocin 2% in polyethylene glycol (PEG) ointment \[Treatment Arm\] is effective in preventing moderate to severe re-infection with Staphylococcus aureus compared with treatment with polyethylene glycol (PEG) ointment \[Placebo Arm\].

What is the current status of trial NCT00108160?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 146 participants. The study started on 2005-04. Estimated completion is 2012-08.

What interventions are being tested in trial NCT00108160?

The interventions under investigation include: Mupirocin Ointment [Treatment] (DRUG), Polyethylene Glycol Ointment [Placebo] (DRUG).

Who is sponsoring clinical trial NCT00108160?

This trial is sponsored by US Department of Veterans Affairs, which has 632 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.